3.73
price down icon3.37%   -0.13
pre-market  Pre-market:  3.75   0.02   +0.54%
loading
Bluebird Bio Inc stock is traded at $3.73, with a volume of 186.35K. It is down -3.37% in the last 24 hours and down -48.55% over the past month. bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
See More
Previous Close:
$3.86
Open:
$3.82
24h Volume:
186.35K
Relative Volume:
0.46
Market Cap:
$36.33M
Revenue:
$21.73M
Net Income/Loss:
$-91.17M
P/E Ratio:
-5.0405
EPS:
-0.74
Net Cash Flow:
$-286.43M
1W Performance:
-9.25%
1M Performance:
-48.55%
6M Performance:
-69.21%
1Y Performance:
-86.58%
1-Day Range:
Value
$3.67
$3.85
1-Week Range:
Value
$3.67
$4.14
52-Week Range:
Value
$3.56
$30.90

Bluebird Bio Inc Stock (BLUE) Company Profile

Name
Name
Bluebird Bio Inc
Name
Phone
339-499-9300
Name
Address
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Name
Employee
375
Name
Twitter
@bluebirdbio
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
BLUE's Discussions on Twitter

Compare BLUE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BLUE
Bluebird Bio Inc
3.73 36.33M 21.73M -91.17M -286.43M -0.74
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-24-25 Upgrade JP Morgan Underweight → Neutral
Nov-15-24 Downgrade BofA Securities Buy → Neutral
Nov-15-24 Downgrade JP Morgan Neutral → Underweight
Aug-15-24 Downgrade JP Morgan Overweight → Neutral
Dec-11-23 Downgrade HSBC Securities Hold → Reduce
Dec-08-23 Upgrade Morgan Stanley Underweight → Equal-Weight
Oct-17-23 Initiated Cantor Fitzgerald Neutral
Sep-06-23 Initiated HSBC Securities Buy
Jul-19-23 Upgrade BofA Securities Neutral → Buy
Jun-01-23 Upgrade Barclays Equal Weight → Overweight
Apr-28-23 Initiated JP Morgan Overweight
Mar-07-23 Initiated Robert W. Baird Outperform
Aug-05-22 Upgrade Barclays Underweight → Equal Weight
Aug-02-22 Upgrade Raymond James Mkt Perform → Outperform
Apr-06-22 Downgrade Cowen Outperform → Market Perform
Mar-07-22 Downgrade Barclays Equal Weight → Underweight
Nov-08-21 Reiterated Barclays Equal Weight
Nov-08-21 Reiterated Canaccord Genuity Hold
Nov-08-21 Downgrade Goldman Neutral → Sell
Nov-08-21 Downgrade Morgan Stanley Equal-Weight → Underweight
Nov-08-21 Reiterated RBC Capital Mkts Sector Perform
Nov-08-21 Reiterated Wedbush Neutral
Nov-08-21 Reiterated Wells Fargo Equal Weight
Aug-10-21 Downgrade Canaccord Genuity Buy → Hold
Aug-10-21 Downgrade Goldman Buy → Neutral
Aug-10-21 Downgrade Wells Fargo Overweight → Equal Weight
Aug-10-21 Resumed William Blair Mkt Perform
Aug-09-21 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-01-21 Downgrade Berenberg Buy → Hold
Mar-10-21 Upgrade Mizuho Neutral → Buy
Feb-17-21 Downgrade JP Morgan Overweight → Neutral
Feb-16-21 Downgrade BofA Securities Buy → Neutral
Feb-16-21 Downgrade Wedbush Outperform → Neutral
Feb-16-21 Downgrade William Blair Outperform → Mkt Perform
Dec-09-20 Downgrade Maxim Group Buy → Hold
Nov-11-20 Initiated Berenberg Buy
Nov-05-20 Downgrade BMO Capital Markets Outperform → Market Perform
Nov-05-20 Downgrade Barclays Overweight → Equal Weight
Nov-05-20 Downgrade Stifel Buy → Hold
Nov-02-20 Upgrade William Blair Mkt Perform → Outperform
Oct-20-20 Initiated Mizuho Buy
May-13-20 Initiated RBC Capital Mkts Outperform
Mar-27-20 Upgrade Stifel Hold → Buy
Feb-19-20 Downgrade Raymond James Outperform → Mkt Perform
Feb-03-20 Resumed BofA/Merrill Buy
Feb-03-20 Upgrade Evercore ISI In-line → Outperform
Dec-13-19 Upgrade Oppenheimer Perform → Outperform
Nov-26-19 Upgrade SVB Leerink Mkt Perform → Outperform
Nov-19-19 Downgrade Evercore ISI Outperform → In-line
Nov-04-19 Upgrade Wedbush Neutral → Outperform
Oct-01-19 Initiated Stifel Hold
Aug-12-19 Downgrade William Blair Outperform → Mkt Perform
Jun-18-19 Upgrade Maxim Group Hold → Buy
View All

Bluebird Bio Inc Stock (BLUE) Latest News

pulisher
Mar 13, 2025

BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc.BLUE - Business Wire

Mar 13, 2025
pulisher
Mar 13, 2025

Gene Therapy Market Future Business Opportunities 2025-2032 | - openPR

Mar 13, 2025
pulisher
Mar 12, 2025

Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M Deal - Dealbreaker

Mar 12, 2025
pulisher
Mar 12, 2025

Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs - BioSpace

Mar 12, 2025
pulisher
Mar 12, 2025

bluebird bio (NASDAQ:BLUE) Coverage Initiated at StockNews.com - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Stem Cell Therapy Market Growth | Trends, Size & Forecast - openPR

Mar 12, 2025
pulisher
Mar 11, 2025

BMS to Acquire Abecma Partner 2seventy bio for $286M - Genetic Engineering & Biotechnology News

Mar 11, 2025
pulisher
Mar 11, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc.BLUE - PR Newswire

Mar 11, 2025
pulisher
Mar 11, 2025

2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M - BioPharma Dive

Mar 11, 2025
pulisher
Mar 11, 2025

Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal - Benzinga

Mar 11, 2025
pulisher
Mar 11, 2025

Bristol Myers Squibb scoops up 2seventy bio for $286M - The Business Journals

Mar 11, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Cuts Stock Holdings in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World

Mar 11, 2025
pulisher
Mar 06, 2025

Bluebird bio’s chief medical officer Richard Colvin sells $2,288 in stock - Investing.com Australia

Mar 06, 2025
pulisher
Mar 05, 2025

Bluebird bio’s chief commercial officer sells $1,959 in stock - Investing.com

Mar 05, 2025
pulisher
Mar 05, 2025

Bluebird bio’s chief commercial officer sells $1,959 in stock By Investing.com - Investing.com Australia

Mar 05, 2025
pulisher
Mar 04, 2025

bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at StockNews.com - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

bluebird bio, Inc. Class Action: Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024BLUE - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio LawsuitBLUE - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Levi & Korsinsky Reminds bluebird bio, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024BLUE - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Lost Money on bluebird bio, Inc. (BLUE)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Multiple Myeloma Treatment Market Size Report 2034 | - openPR

Mar 03, 2025
pulisher
Mar 03, 2025

Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024BLUE - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 02, 2025

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc.(BLUE) Shareholders - ACCESS Newswire

Mar 02, 2025
pulisher
Mar 01, 2025

BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire

Mar 01, 2025
pulisher
Mar 01, 2025

bluebird bio, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your RightsBLUE - ACCESS Newswire

Mar 01, 2025
pulisher
Feb 28, 2025

Turbulence at the FDA & bluebird Bio’s sale - STAT

Feb 28, 2025
pulisher
Feb 28, 2025

bluebird bio stock slides for second day on buyout news - MSN

Feb 28, 2025
pulisher
Feb 28, 2025

Shareholder Rights Advocates at Levi & Korsinsky Investigate bluebird bio, Inc. (BLUE) Regarding Possible Securities Fraud Violations - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

Drug and Gene Delivery Devices Market Growth in Future Scope - openPR

Feb 28, 2025
pulisher
Feb 27, 2025

Bluebird bio chief business officer Joseph Vittiglio sells $1,759 in stock - MSN

Feb 27, 2025
pulisher
Feb 27, 2025

Levi & Korsinsky Reminds bluebird bio Investors of the Ongoing Investigation into Potential Violations of Securities LawsBLUE - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

BLUE DEADLINE ALERT: Bernstein Liebhard LLP Reminds bluebird bio, Inc. Investors of Upcoming Deadline - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Shareholders that lost money on bluebird bio, Inc. (BLUE) should contact Levi & Korsinsky about pending Class ActionBLUE - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 26, 2025

Contrasting bluebird bio (NASDAQ:BLUE) and Valneva (NASDAQ:VALN) - Defense World

Feb 26, 2025
pulisher
Feb 25, 2025

Carlyle and SK Capital’s Acquisition of bluebird bio - Global Legal Chronicle

Feb 25, 2025
pulisher
Feb 25, 2025

bluebird bio (NASDAQ:BLUE) Given New $5.00 Price Target at Wells Fargo & Company - Defense World

Feb 25, 2025
pulisher
Feb 24, 2025

Bluebird bio stock slides for second day on buyout news (NASDAQ:BLUE) - Seeking Alpha

Feb 24, 2025
pulisher
Feb 24, 2025

JPMorgan Upgrades bluebird bio to Neutral From Underweight -February 24, 2025 at 07:36 am EST - Marketscreener.com

Feb 24, 2025
pulisher
Feb 24, 2025

JP Morgan Upgrades bluebird bio (BLUE) - Nasdaq

Feb 24, 2025
pulisher
Feb 24, 2025

Troubled gene therapy player bluebird sold for a song - pharmaphorum

Feb 24, 2025
pulisher
Feb 24, 2025

Amneal pharma, Aramark, Bluebird Bio - TradingView

Feb 24, 2025
pulisher
Feb 24, 2025

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital - BioSpace

Feb 24, 2025
pulisher
Feb 23, 2025

Bluebird Bio to Be Acquired by Carlyle Group, SK Capital - MSN

Feb 23, 2025
pulisher
Feb 23, 2025

StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow - Genetic Engineering & Biotechnology News

Feb 23, 2025
pulisher
Feb 23, 2025

bluebird bio announces take-private deal with Carlyle and SK Capital - MSN

Feb 23, 2025
pulisher
Feb 23, 2025

IMMINENT BLUE DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds bluebird bio, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire

Feb 23, 2025
pulisher
Feb 23, 2025

bluebird bio plunges after take-private deal with Carlyle and SK Capital - MSN

Feb 23, 2025
pulisher
Feb 22, 2025

Private equity firms rescue bluebird bio out of its misery - The Pharma Letter

Feb 22, 2025
pulisher
Feb 22, 2025

bluebird bio Sees Unusually High Options Volume (NASDAQ:BLUE) - Defense World

Feb 22, 2025
pulisher
Feb 22, 2025

Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker - MSN

Feb 22, 2025
pulisher
Feb 22, 2025

Gene therapy maker bluebird to go private in discounted deal amid cash crunch - MSN

Feb 22, 2025

Bluebird Bio Inc Stock (BLUE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):